Open AccessStatins in the treatment and the prevention of the progression of atherosclerosis of patients with coronary heart disease
Author(s) -
Т. Е. Морозова,
О. А. Вартанова
Publication year - 2013
Publication title -
cardiosomatika
Language(s) - English
Resource type - Journals
eISSN - 2658-5707
pISSN - 2221-7185
DOI - 10.26442/cs45010
Subject(s) - rosuvastatin , tolerability , medicine , statin , coronary heart disease , coronary atherosclerosis , disease , cardiology , cholesterol , atherosclerotic cardiovascular disease , coronary disease , adverse effect
Statins, the most common drugs to lower lipid levels, are «strategic» products for the treatment of patients with coronary heart disease (CHD), atherosclerosis, having the ability to reduce the cardiovascular and total mortality. This class of drugs can slow down the course of atherosclerosis and makes it more benign. A special place among statin places rosuvastatin (Crestor®, «AstraZeneca») due to his number of advantages of pharmacological and clinical properties. Compared with other statins, he has a far more powerful inhibition of the enzyme by metansulfonilamidnoy group and the most hypolipidemic activity (reduction of LDL cholesterol by 45–50% from baseline) in combination with the good tolerability and economic advantages.